Advanced search
Publication Cover
Cancer Investigation Volume 2, 1984 - Issue 3
Submit an article Journal homepage
4
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Vinblastine, Bleomycin, and cis-Platin as Salvage Therapy for MOPP Treated Patients with Hodgkin's Lymphoma

Michael P Corder Department of Internal Medicine College of Medicine University of Iowa, Iowa City, Iowa
,
Gerald H Clamon Department of Internal Medicine College of Medicine University of Iowa, Iowa City, Iowa
&
Martin Wiesenfeld Department of Internal Medicine College of Medicine University of Iowa, Iowa City, Iowa
Pages 193-198 | Published online: 11 Jun 2009

References

  • Weick JK, Jones SE, Haut A, et al: Treatment of recurrent lymphomas with vincristine, BCNU, doxorubicin, and prednisone (VBAP): A Southwest Oncology Group Study. Cancer Treat Rep 65:611–614, 1981.
  • Fisher RI, DeVita VT, Hubbard SP, et al: Prolonged diseasefree survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90:761–763, 1979.
  • Einhorn LH, Williams SD, Stevens E, et al: Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. Cancer 51:1348–1352, 1983.
  • Tannir N, Hagemeister F, Velasquez W, et al: Long-term follOW-Up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol 1:432–438, 1983.
  • Dady PJ, McElwain TJ, Austin DE, et al: Five years' experience with Ch1 VPP: Effective low-toxicity combination chemotherapy for Hodgkin's disease. Br J Cancer 45:851–859, 1982.
  • Santoro A, Bonfante V, Bonadona G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 96:139–143, 1982.
  • Clamon GH, and Corder MP: ABVD treatment of MOPP failures in Hodgkin disease: A re-examination of goals of salvage therapy. Cancer Treat Rep 62:363–367, 1978.
  • Krikorian JG, Portlock CS, and Rosenberg SA: Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer 41: 2107–2111, 1978.
  • Einhorn LH and Donahue J: cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293–298, 1977.
  • Krikorian JG, Daniels JR, Brown BW, et al: Variables for predicting serious toxicity (vinblastine dose, performance status, prior therapeutic experience): Chemotherapy for metastatic testicular cancer with cis-dichlorodiammine-platinum (II), vinblastine, and bleomycin. Cancer Treat Rep 62:1455–1463, 1978.
  • Blum RH, Carter SK and Agre K: A clinical review of bleomycin-A new antineoplastic agent. Cancer 31:903–914, 1973.
  • Corder MP, Elliott TE, Maguire LC, et al: Phase II study of cis-dichlorodiammineplatinum (II) in Stage IVB Hodgkin's disease. Cancer Treat Rep 63:763–766, 1979.
  • F1atow FA, Ultmann JE, Hyman GA, et al: Treatment of advanced Hodgkin's disease with vinblastine (NSC-49842) or procarbazine (NSC-77213). Cancer Chemo Rep 53:39–47, 1969.
  • Sohier WD, Wong RKL, Aisenberg AC: Vinblastine in the treatment of advanced Hodgkin's disease. Cancer 22:467–472, 1968.
  • Devita VT, Simon RM, Hubbard SM, et al: Curability of advanced Hodgkin's disease with chemotherapy: Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92:587–597, 1980.
  • Fisher RI, DeVita VT, Hubbard SP, et al: Prolonged disease free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90:761–763, 1979.
  • Dady PJ, McElwain TJ, Austin DE, et al: Five years' experience with ChlVPP: Effective low-toxicity combination chemotherapy for Hodgkin's disease. Br J Cancer 45:851–859, 1982.
  • Liepman MK, Wheeler RH, Zuckerman KS, et al: Combination chemotherapy of refractory lymphoma with cis-dichlorodiamine-platinum, vinblastine, and bleomycin. Cancer 50:2736–2739, 1982.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.